February 20, 2012
Cellartis AB to be partner in a major multinational IMI project supported by the European Commission and the European Pharmaceutical Industry
February 13, 2012
Cellartis AB will be a partner in the 4DCellFate program, an EU-project aiming to better understand stem cell differentation
February 6th, 2012
Cellartis to be partner in TissueGen, a major multinational stem cell project funded by the European Comission
January 23, 2012
Cellartis is a partner in CardioNet, an EU-project with the aim to develop novel therapeutic tools for identification of heart disease
January 10, 2012
Cellartis is a partner in InnovaLiv, a major multinational regenerative medicine project funded by the European Commission
September 15, 2011
Swedish stem cell company Cellartis to be acquired by French biotech company Cellectis
September 12, 2011
For the first time, human hepatocyte-like cells derived from pluripotent stem cells prove to be an efficient in vitro toxicity model.
August 25, 2011
Mats Lundwall has resigned as CEO for Cellartis AB and the board of directors have appointed Johan Hyllner, Cellartis’ CSO, as the company’s new CEO.
July 1, 2011
Cellartis' stem cell-derived human heart muscle cells represent a viable alternative to animal testing.
February 21, 2011
PRESS RELEASE - Cellartis’ human pluripotent stem cell lines once again pass the scrutiny of the NIH
June 7, 2010
Cellartis is a partner in a ten million Euro R&D project funded through a unique initiative by the European Commission and the European cosmetic industry
read more ...
March 31, 2010
Cellartis releases a new generation 2D Cardiomyocyte product, derived from pluripotent stem cells, for drug discovery and toxicity testing.
April 30, 2009
Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes.
February 16, 2009
AstraZeneca and Cellartis extend their collaboration to develop new way to test drug safety using stem cells.